Publications by authors named "B Dubashi"
Article Synopsis
- - Gemcitabine is a cancer drug effective against tumors like pancreatic and lung cancers, but its effectiveness has been declining due to genetic instability, prompting research into gene polymorphisms that may affect drug metabolism.
- - This study analyzed gene polymorphism frequencies related to gemcitabine metabolism in healthy and lung cancer patients from Southern India, utilizing real-time polymerase chain reaction to genotype 184 healthy individuals and 123 lung cancer patients.
- - Results showed significant differences in allele frequencies for specific SNPs between the South Indian population and the 1000 Genomes Project, with one SNP showing a potential protective effect against lung cancer.
Generic Dabigatran for Cancer-Associated Venous Thromboembolism: Real-World Data.
Indian J Hematol Blood Transfus
October 2024
Objective: To study the kinetics of blood count nadir and time to recovery and find its association with clinical outcomes in a cohort of Acute Lymphoblastic Leukemia (ALL).
Methods: Data from 243 cases treated between January 2018 to December 2020 was retrospectively analysed. Along with baseline data, serial measures of peripheral blood counts, nadir, and time to partial and complete recovery of counts during course of induction chemotherapy were recorded.
Background Tyrosine kinase inhibitors have revolutionized the treatment of chronic myeloid leukemia (CML) since the beginning of the century. However, resistance to therapy and the progression of disease tend to occur in certain patients. The bone marrow microenvironment may play a role in the disease outcome.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to assess if adding docetaxel (D) to standard chemotherapy regimens improved overall survival (OS) in patients with advanced HER2-negative gastroesophageal junction and gastric adenocarcinomas.
- Out of 324 patients enrolled, the analysis showed that FOLFOX/CAPOX provided a median OS of 10.1 months, while the DOF/DOX regimen resulted in 8.9 months, with no significant survival advantage from the addition of docetaxel (P = .70).
- The study also noted higher rates of severe neutropenia and neuropathy in the DOF/DOX group and identified a surprisingly high incidence of BRCA1 and BRCA2 alterations